Lovenox sales decline

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) said third quarter sales of Lovenox enoxaparin fell 26% to EUR 537 million ($732 million) compared to 3Q09

Read the full 225 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE